Daniel A. Vallera

Learn More
Background:Potency, immunogenicity, and toxicity are three problems that limit the use of targeted toxins in solid tumour therapy.Methods:To address potency, we used genetic engineering to develop a(More)
DTAT13, a novel recombinant bispecific immunotoxin (IT) consisting of truncated diphtheria toxin, an amino-terminal (AT) fragment of the urokinase-type plasminogen activator (uPa), and a fragment of(More)
A bispecific immunotoxin (IT) called DTAT13 was synthesized in order to target simultaneously the urokinase-type plasminogen activator receptor (uPAR)-expressing tumor neovasculature and IL-13(More)